Retrospective cohort study finds cancer cachexia predicts outcomes in EGFR-mutant NSCLC post-TKI, suggesting treatment guidance.
BACKGROUND/AIM: ) remains unclear. This multicenter retrospective cohort study evaluated the impact of cancer cachexia on treatment selection after the development of resistance to EGFR tyrosine kinase inhibitors (TKIs). PATIENTS AND Cancer cachexia was diagnosed based on specific weight loss criteria and laboratory data. Propensity score matching was performed to adjust for baseline differences, and survival outcomes were compared. CONCLUSION: -mutant NSCLC.
No takes yet. Share an insight, caveat, or question.
Nakatani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: